Literature DB >> 28864149

Anticancer potential of aminomethylidene-diazinanes I. Synthesis of arylaminomethylidene of diazinetriones and its cytotoxic effects tested in glioblastoma cells.

Nichole A Pianovich1, Mathew Dean2, Adam Lassak2, Krzysztof Reiss2, Branko S Jursic3.   

Abstract

Diazinane and aryl moieties with vinylamine linkers were synthesized to investigate the importance of their structural variations as potential anti-glioblastoma agents. Structural variations incorporated on to the diazinane moiety included oxa and thio derivatives, each with a variety of nitrogen-bound substituents. The size and shape of the aromatic moiety was varied, with the final variation introducing two carbonyl groups, yielding a substituted anthraquinone. Readily available diazinanes and aryl amines were used asan advantageous foundation. Several parameters were calculated whilst engineering these compounds, including: ClogP, molecular polarizability, polar surface area, minimal molecular projected area, and pKa. In addition, a simple and efficient procedure was developed to synthesize these compounds. It was demonstrated that a vinylamine with 1,3-diazinane-2,4,6-trione and 1-anthraquinone moiety is the most promising drug candidate causing almost 70% of LN229 tumor cell death at 1µg/ml. In addition, its molecular polarizability, polar surface area and minimal molecular projected area indicate a possible potential of this molecule for crossing BBB.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Anticancer; Carbamoyl; Diazinane; Glioblastoma; Merbarone

Mesh:

Substances:

Year:  2017        PMID: 28864149      PMCID: PMC5870872          DOI: 10.1016/j.bmc.2017.08.020

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  31 in total

Review 1.  Lipophilicity and its relationship with passive drug permeation.

Authors:  Xiangli Liu; Bernard Testa; Alfred Fahr
Journal:  Pharm Res       Date:  2010-10-30       Impact factor: 4.200

Review 2.  Structure-brain exposure relationships.

Authors:  Stephen A Hitchcock; Lewis D Pennington
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

3.  Phase II trial of merbarone in patients with malignant brain tumors.

Authors:  U R Malik; J P Dutcher; G Caliendo; P Lasala; R Mitnick; P H Wiernik
Journal:  Med Oncol       Date:  1997 Sep-Dec       Impact factor: 3.064

4.  Temozolomide: mechanisms of action, repair and resistance.

Authors:  Jihong Zhang; Malcolm F G Stevens; Tracey D Bradshaw
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

5.  Synthesis of N-aryl and N-arylcarbamoylamino derivatives of 1,3-diazinane-5-carboxamide and their activity against glioblastoma LN-229 cell line.

Authors:  Rebecca J Hron; Branko S Jursic; Donna M Neumann
Journal:  Bioorg Med Chem       Date:  2016-10-04       Impact factor: 3.641

6.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

Review 7.  Medicinal chemical properties of successful central nervous system drugs.

Authors:  Hassan Pajouhesh; George R Lenz
Journal:  NeuroRx       Date:  2005-10

8.  Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage.

Authors:  J M Fortune; N Osheroff
Journal:  J Biol Chem       Date:  1998-07-10       Impact factor: 5.157

9.  Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors.

Authors:  Dali Yin; Xiao Wang; Bindu M Konda; John M Ong; Jinwei Hu; Manuel R Sacapano; Minhee K Ko; Andres J Espinoza; Dwain K Irvin; Yan Shu; Keith L Black
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

10.  Inhibition of ERβ induces resistance to cisplatin by enhancing Rad51-mediated DNA repair in human medulloblastoma cell lines.

Authors:  Anna Wilk; Agnieszka Waligorska; Piotr Waligorski; Augusto Ochoa; Krzysztof Reiss
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

View more
  1 in total

Review 1.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.